Allopurinol is the drug of choice for treating elevated serum uric acid
Allopurinol is strongly recommended as the preferred first-line agent for all patients requiring urate-lowering therapy, including those with chronic kidney disease stage ≥3 1. This recommendation is based on its proven efficacy when dosed appropriately, excellent tolerability, safety profile, and significantly lower cost compared to alternatives.
Starting Dose and Titration Strategy
Begin allopurinol at ≤100 mg/day (even lower doses of ≤50 mg/day in patients with CKD stage ≥3) 1. This low-dose initiation is critical to mitigate the risk of allopurinol hypersensitivity syndrome (AHS), which is associated with higher starting doses and presence of CKD 1.
- Titrate upward by 100 mg increments every 2-4 weeks 2
- Target serum uric acid <6 mg/dL for standard cases
- Target <5 mg/dL for severe gout (tophi, chronic arthropathy, frequent attacks) 2
- Maximum FDA-approved dose is 800 mg/day 1
- Patients often require doses >300 mg/day to achieve target 1
Essential Flare Prophylaxis
Always initiate concomitant anti-inflammatory prophylaxis when starting urate-lowering therapy 1. The 2020 ACR guidelines strongly recommend prophylaxis for 3-6 months (not <3 months), with ongoing evaluation 1.
Options include:
- Colchicine 0.5-1 mg/day (reduce dose in renal impairment) 2
- Low-dose NSAIDs if colchicine contraindicated
- Prednisone/prednisolone as alternative
Critical caveat: Avoid co-prescribing colchicine with strong P-glycoprotein or CYP3A4 inhibitors (cyclosporin, clarithromycin) due to neurotoxicity and muscular toxicity risk 2.
Alternative Agents
If allopurinol fails to achieve target at maximum appropriate dose or is not tolerated:
- Febuxostat (start ≤40 mg/day, titrate upward) 1
- Uricosurics (probenecid 500 mg once-twice daily) - only in normal renal function, no history of kidney stones 2
For CKD stage ≥3: Strongly prefer xanthine oxidase inhibitors (allopurinol or febuxostat) over probenecid 1.
Pegloticase is strongly recommended AGAINST as first-line therapy due to cost, safety concerns, and favorable benefit-to-harm ratios of other untried options 1. Reserve for crystal-proven severe debilitating chronic tophaceous gout with poor quality of life when all other agents at maximal doses (including combinations) have failed 2.
Important Clinical Pitfalls
Do NOT treat asymptomatic hyperuricemia - The 2020 ACR conditionally recommends against initiating pharmacologic ULT in patients with elevated uric acid but no gout flares or tophi, even with levels >6.8 mg/dL 1. Number needed to treat is 24 patients for 3 years to prevent a single incident gout flare.
Adjust allopurinol dose in renal impairment - Maximum dosage should be adjusted to creatinine clearance, but patients may still require titration above 300 mg/day to achieve target 1, 2.
Maintain lifelong therapy - Once initiated, serum uric acid <6 mg/dL should be maintained lifelong to prevent crystal reaccumulation 2.
The evidence base for allopurinol as first-line therapy is robust, with both the 2020 ACR 1 and 2017 EULAR 2 guidelines providing strong, concordant recommendations based on moderate-quality evidence.